

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/065122 A1

- (51) International Patent Classification⁷: **G01N 33/50**, C12Q 1/34, 1/37
- (21) International Application Number: **PCT/IT01/00069**
- (22) International Filing Date: 15 February 2001 (15.02.2001)
- (25) Filing Language: Italian
- (26) Publication Language: English
- (71) Applicant (*for all designated States except US*): **UNIBIO S.R.L.** [IT/IT]; Via Guerrazzi, 28/6, I-40125 Bologna (IT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **CAUCI, Sabina** [IT/IT]; Piazza Cavour, 25, I-34074 Monfalcone (IT).
- (74) Agents: **LONG, Giorgio** et al.; Jacobacci & Partners S.p.A., Via Senato, 8, I-20121 Milano (IT).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/065122 A1

(54) Title: ENZYMATIC TEST FOR THE DETERMINATION OF THE RISK OF PATHOLOGIES RELATED TO THE PRESENCE OF SIALIDASE OR PROLIDASE ACTIVITY IN WOMEN BODY FLUID SAMPLES

(57) Abstract: The current invention describes a method for the determination of the risk of pathologies related to the presence of sialidase and/or prolidase activity in body fluid samples of women, comprising the following steps in order: a) determination of the levels of sialidase and/or prolidase activity in said sample of body fluid; b) comparison of said levels of sialidase and/or prolidase activity with ranges of prefixed values of said activity; c) calculation of the risk factor. This method resulted particularly efficient in permitting to obtain an accurate and reliable evaluation of the risk of pathologies related to the presence of sialidase and/or prolidase activity in samples of body fluid of women. Consequently, this method gives the physician an efficient tool to decide whether or not to administer a pharmacological therapy.

ENZYMATIC TEST FOR THE DETERMINATION OF THE RISK OF PATHOLOGIES RELATED TO THE
PRESENCE OF SIALIDASE OR PROLIDASE ACTIVITY IN WOMEN BODY FLUID SAMPLES

5 The current invention describes a method for the evaluation of the risk of
pathologies related to sialidase and/or prolidase activity in samples of body fluid of
women.

 In particular, this invention provides a method for the qualitative and
quantitative determination of the risk of pathologies as, for example, low birth
10 weight (LBW), preterm delivery (PTD), preterm rupture of membranes,
intraamniotic infections, spontaneous abortion, endometritis, post-partum or post-
gynecologic surgery infections, upper genital tract infections (PID) which cause
infertility, cervicitis, susceptibility to sexually transmitted diseases as viral infections
from papillomavirus (HPV) and human immunodeficiency virus (HIV), and vertical
15 transmission of HIV infection.

 Low birth weight (LBW), primarily due to preterm birth (PTD), is the
main risk factor for neonatal morbidity, mortality and long term infant neurological
disorders.

 Most cases of low birth weight have no recognized causal factors, making
20 current prevention strategies ineffective. However, several investigations have shown
that bacterial vaginosis (BV) is associated with preterm delivery (PTD), with
increased relative risk from 1.4 to 6.9 fold in respect to absence of BV, preterm
delivery of low-weight infants, early and late miscarriage, and in general with
maternal complications. Moreover, recently bacterial vaginosis was associated with
25 increased risk of sexual acquisition of the viral infection by HIV and of vertical

mother-to-child HIV transmission. Bacterial vaginosis prevalence is about 10% in non-pregnant women and about 15% in pregnant women in Western Europe, from 10 to 30% in US pregnant women, over 30% in colored African origin women, over 60% in women attending sexually transmitted disease clinics. Anyway, it is to be
5 noted that only a small percentage of women with BV have adverse pregnancy outcomes or acquire HIV infection, among subjects at elevated risk of HIV viral exposure, so there is the need to have selective markers to individuate patients at elevated risk who need to be therapeutically treated.

Bacterial vaginosis is caused by different bacterial species comprising *G. vaginalis*, *Bacteroides* spp., *Prevotella* spp. and *Mobiluncus* spp., *Ureaplasma urealyticum* and *Mycoplasma hominis*. The pathogenesis of bacterial vaginosis is still
10 obscure and not always the presence of such pathologic condition is easy to diagnose.

In particular, it is not known what triggers the shift from the normal
15 lactobacilli colonization to the altered vaginal flora, or which degree of the vaginal microbial flora alteration is indicative of a real pathologic condition.

A crucial issue in bacterial vaginosis is the synergy between *G. vaginalis* and anaerobic bacteria.

G. vaginalis is found in high titers in over the 95% of bacterial vaginosis
20 cases, whereas low titers of *G. vaginalis* colonization are found also in women without bacterial vaginosis.

However, a strict correlation between *G. vaginalis* colonization and the condition of bacterial vaginosis has been demonstrated.

The only fully characterized virulence factor released by *G. vaginalis* is a β -
25 hemolytic toxin (Gvh) having a molecular weight of about 59,000 Dalton.

Furthermore, it has been shown that about half of the non-pregnant women develop an immune response against Gvh eliciting IgA antibodies at the vaginal mucosa level. The absence of anti-Gvh IgA antibodies in women with BV is mainly due to the inactivation of IgA and this phenomenon is related to the presence of high
5 levels of vaginal sialidase activity. Such inactivation derives from a structural impairment of IgA likely due to the hydrolytic action of an array of factors released by anaerobic bacteria.

Presently it is not known which factors of the antimicrobial host defense are compromised or which microbial virulence factor(s) elicits the IgA cleavage in a
10 subgroup of women with bacterial vaginosis.

Above all, it is not yet established if this condition is associated with increased risk of BV complications.

Such an uncertain definition makes clinicians to face the problem whether or not administer a pharmacological therapy to women with bacterial vaginosis. It is
15 well known that two different drugs are used to treat bacterial vaginosis: metronidazole or clindamycin. Both these drugs show a main drawback consisting in relevant adverse side effects, in particular metronidazole can give gastrointestinal symptoms, and is considered a teratogen agent, so it is not recommended during pregnancy, on the other hand clindamycin can cause diarrhea and
20 pseudomembranous colitis which may be lethal. Moreover both such antibiotics can cause yeast vaginitis.

For the above described reasons it is highly desirable the development of a method to determine the risk of pathologic complications as, for example, low birth weight (LBW), preterm birth (PTD), spontaneous abortion, premature rupture of
25 membranes, endometritis, acquisition of HIV infection, and of HPV infection (which

causes cervical intraepithelial neoplasia), upper genital tract infections (PID), post-partum and post-gynecologic surgery infections.

The present invention provides a reliable method to solve the problem of the risk determination of the above-described complications by furnishing the physician
5 a valuable tool to decide whether or not administer a pharmacological therapy.

Such a problem is solved by a method for determination of risk of pathologies as expressed in the main enclosed claim.

Further features and advantages of the method of the present invention will be highlighted by the subsequent description of preferred embodiments, given at
10 indicative and not limitative title.

For the setting up of the method of the current invention clinical cases have been studied and compared with controls of women with no recognized pathologic conditions.

In particular, 116 women who had low birth weight babies (LBW), 86
15 women who had a preterm delivery (PTD), and 417 women who had normal birth weight babies at term of gestation (NTD) were examined.

The presence of sialidase and/or prolidase activity was detected in the vaginal fluid samples of all these women, moreover the levels of said sialidase and prolidase activity were evaluated.

20 Sialidases are enzymes produced by bacteria and are involved in the pathogenesis of several diseases. These enzymes provoke the hydrolysis of sialic acid from various glycoproteins including IgA, altering the immune response.

Prolidases are proteolytic enzymes produced by bacteria to favor the cell infiltration. These enzymes are able to activate cytokines and other immune
25 mediators.

The sialidase activity was determined by incubation of 50 µl of the vaginal fluid sample with 50 µl of a substrate at pH 5.0, with a procedure described by Cauci et al., *Am J Obstet Gynecol* 1998; 178: 511-5. Specific activity was expressed as nanomoles of methoxyphenol produced from conversion of the substrate and
5 calculated by comparison with a standard curve of pure methoxyphenol. The levels of sialidase activity were evaluated as: no activity for values below 0.19 nmol of methoxyphenol, +1 cutoff for values equal or above 0.19 nmol of methoxyphenol; +2 cutoff for values equal or above 0.38 nmol of methoxyphenol; +3 cutoff for values equal or above 2.50 nmol of methoxyphenol, and +4 cutoff for values equal or above
10 5.0 nmol of methoxyphenol.

Prolidase activity was determined as described by Cauci et al., *J Infect Dis* 1998; 178:1698-706. The levels of prolidase activity were evaluated as: no activity for values below 22 mOD, +1 cutoff for values equal or above 22 mOD; +2 cutoff for values equal or above 44 mOD; +3 cutoff for values equal or above 1000 mOD
15 and +4 cutoff for values equal or above 2000 mOD.

The +1 cutoffs of sialidase and prolidase activity were calculated by the mean value plus one standard deviation measured in a healthy control population (that is devoid of any vaginal symptom and with no microbial vaginal colonization except lactobacilli). The +2 cutoff was obtained by doubling the +1 cutoff. The +3 cutoff
20 was obtained by halving the +4 cutoff.

In particular, to set up the method of this invention said values of sialidase and prolidase activity were associated with LBW and PTD.

The following Table 1 shows data analyzed as percentage of women which had low birth weight babies (LBW), preterm delivery (PTD) or normal term delivery
25 (NTD, controls), whereas data in bold show the ratio (odds ratio, OR) between the

percentage of women with LBW or PTD and the percentage of NTD women, respectively. This value was calculated and corrected by a standard factor by the SPSS computer statistic program.

In particular, the vaginal fluid samples were obtained from women in the first
5 or in the second trimester of gestational age, and, preferably, in the period ranging from the seventh to the twenty-fourth full week of gestation.

These groups of women have been further subdivided on the basis of the presence, in the vaginal fluids samples, of sialidase activity alone, of prolidase activity alone, of these enzymatic activities and a $\text{pH} \geq 4.7$, of these enzymatic
10 activities and the pathologic condition bacterial vaginosis (BV), or of these enzymatic activities and the *G. vaginalis* bacterium.

TABLE 1

		Positive % OR			
Measured parameter and/or vaginal colonization		NTD n=417	LBW n=116		PTD n=86
10	Sialidase activity				
	≥ +1	15.3	28.7	2.2	20.0 1.4
	≥ +2	10.3	18.3	1.9	11.8 1.2
	≥ +3	3.8	7.8	2.1	4.7 1.2
	≥ +4	1.0	3.5	3.7	2.4 2.5
15	Prolidase activity				
	≥ +1	33.7	41.6	1.4	34.9 1.1
	≥ +2	26.0	37.2	1.7	24.1 0.9
	≥ +3	3.9	7.1	1.9	6.0 1.6
	≥ +4	1.0	4.4	4.8	3.6 3.9
20	pH ≥ 4.7	30.5	37.1	1.3	32.6 1.1
	pH ≥ 4.7 and Sialidase activity				
25	≥ +1	9.8	19.0	2.0	11.6 1.2
	≥ +2	7.9	13.8	1.8	10.5 1.4
	≥ +3	3.8	7.8	2.1	4.7 1.2
	≥ +4	1.0	3.4	3.6	2.3 2.4
	30	pH ≥ 4.7 and Prolidase activity			
≥ +1		20.9	31.0	1.6	25.6 1.3
≥ +2		18.5	30.2	1.7	20.9 1.2
≥ +3		3.6	6.0	1.8	4.7 1.4
≥ +4		0.7	3.4	5.1	2.3 3.5
35	BV	14.6	20.7	1.5	12.8 0.9
	BV and Sialidase activity				
40	≥ +1	9.1	15.7	1.9	7.1 0.8
	≥ +2	7.4	12.2	1.7	7.1 0.9
	≥ +3	3.8	7.8	2.1	4.7 1.2
	≥ +4	1.0	3.5	3.7	2.4 2.5
	45	BV and Prolidase activity			
≥ +1		13.5	18.6	1.5	12.0 0.9
≥ +2		13.0	18.6	1.5	10.8 0.8
≥ +3		2.7	3.5	1.3	2.4 0.9
≥ +4		0.2	2.7	11.3	1.2 5.0

TABLE 1 (continuation)

		Positive % OR			
5	Measured parameter and/or vaginal colonization	NTD n=417	LBW n=116	PTD n=86	
	<i>G. vaginalis</i>	36.2	42.2	1.3	36.0 1.0
	<i>G. vaginalis</i> and Sialidase activity				
10	≥ +1	11.0	18.3	1.8	11.8 1.1
	≥ +2	8.2	13.0	1.7	9.4 1.2
	≥ +3	3.8	7.8	2.1	4.7 1.3
	≥ +4	1.0	3.5	3.7	2.4 2.5
15	<i>G. vaginalis</i> and Prolidase activity				
	≥ +1	23.4	31.0	1.5	26.5 1.2
	≥ +2	21.0	30.1	1.7	22.9 1.1
	≥ +3	3.6	7.1	2.0	6.0 1.7
20	≥ +4	0.7	4.4	6.4	3.6 5.2

The main result shown in Table 1 is the OR value as it represents the index of risk of low birth weight (LBW) or of preterm birth (PTD).

If this ratio is lower than 1 it means that the woman has no or low risk of complications. A ratio ranging from 1 to 2 is associated with a medium risk of complications. If this ratio is comprised between 2 and 4 it means that the woman has a high risk of complications. Finally, if this ratio is higher than 4 it means that the woman has a very high risk of low birth weight or preterm birth.

In particular, and at title of example, a medium risk corresponding to an OR value equal 2 means that the patient has a twofold risk of complications compared to a normal woman, that is, in other words, a risk 100% higher.

Preferably, this result can be point out with a score: – meaning a low or no risk, + meaning a medium risk, ++ meaning a high risk, and +++ meaning a very high risk.

Table 1 highlights that the OR value has an essentially increasing profile in relation to the increase of the levels of sialidase or prolidase activity.

In particular, for levels of sialidase activity from +1 to +3 cutoffs the OR values for LBW are comprised between 2 and 4, whereas the OR values for PTD are
5 comprised between 1 and 2. Consequently, said levels of sialidase activity in vaginal fluid samples, regardless to the BV condition, and regardless to the presence of *Gardnerella vaginalis*, are indicative of a high risk for LBW and a medium risk for PTD.

The OR values are in the range from 2 and 4 both for LBW and PTD for
10 levels of sialidase activity equal or higher than +4. Consequently, the risk for LBW or PTD is high.

Likewise, for levels of prolidase activity from +1 to +3 cutoffs the OR values are comprised between 1 and 2, both for LBW and PTD. Therefore, the risk for LBW and PTD is medium.

15 On the other hand, for levels of prolidase activity equal or higher than +4, the OR value is higher than 4 for LBW and comprised between 2 and 4 for PTD. Consequently, the risk for LBW is very high, whereas the risk for PTD is medium.

From the analysis of the clinical data shown in Table 1, it is possible to relate the risk for LBW or PTD with the levels of sialidase and/or prolidase activity
20 detected in the body fluid of the patient, preferably in a sample of vaginal fluid.

On the grounds of the results just shown, and according to the current invention, a method has been set up for the determination of the risk of pathologies related to the presence of sialidase or prolidase activity in samples of body fluid, as low birth weight (LBW), preterm birth (PTD), premature rupture of membranes,
25 intraamniotic infections, spontaneous abortion, endometritis, post-partum and post-

gynecologic surgery infections, upper genital tract infections (PID) which cause infertility, cervicitis, susceptibility to sexually transmitted diseases as viral infections from papillomavirus (HPV) and human immunodeficiency virus (HIV), and vertical transmission of HIV infection.

5 Said method comprises the following steps in the order:

- a) determination of levels of sialidase and/or prolidase activity in said body fluid sample;
- b) comparison of such levels of sialidase and/or prolidase activity with prefixed ranges of said activities.
- 10 c) calculation of the risk factor.

It is so evident that an effective method has been devised to evaluate the risk of pathologies related to the presence of sialidase and/or prolidase activity in samples of body fluid of women. Profitably, this method allows to have a very accurate and reliable evaluation.

15 Furthermore, in Table 1, as previously mentioned, data obtained from the analysis of vaginal fluid samples of women having vaginal $\text{pH} \geq 4.7$ and sialidase or prolidase activity are reported.

As can be noted, in women having vaginal $\text{pH} \geq 4.7$ for levels of sialidase activity comprised between +1 and +2, the OR values for LBW or for PTD are in the
20 range from 1 to 2. Consequently, the risk for LBW and PTD is medium. Whereas, for levels of sialidase activity +3, the OR value for LBW is comprised between 2 and 4 and the OR value for PTD is comprised between 1 and 2. It follows that the risk for LBW is high, whereas the risk for PTD is medium. Finally, for levels of sialidase activity +4, the OR value for LBW and PTD is in the range from 2 to 4 so the
25 corresponding risk is high.

In respect to levels of prolidase activity from +1 to +3 in samples of vaginal fluid with $\text{pH} \geq 4.7$, the OR values for LBW and PTD are in the range from 1 to 2 so that the corresponding risk is medium. At variance, for levels of prolidase activity +4, the OR value is higher than 4 for LBW and in the range from 2 to 4 for PTD.

5 Consequently, the risk for LBW is very high, whereas the risk for PTD is high.

According to an embodiment of the invention, the method can be carried out in samples of vaginal fluid with a pH equal or higher than 4.7.

Furthermore, in Table 1, as previously mentioned, data from the analysis of samples of vaginal fluid from women with BV and in which sialidase or prolidase
10 activity was measured are reported.

In particular, in women with BV for levels of sialidase activity comprised between +1 and +2, the OR values for LBW are in the range from 1 to 2, whereas the OR values for PTD are below 1, so it follows that the risk for LBW is medium, whereas the risk for PTD is low or absent. For levels of sialidase activity comprised
15 between +3 and +4, the OR values for LBW are in the range from 2 to 4, so it follows that the risk for LBW is medium.

Instead, as regards to PTD, levels equal or above +3 can be distinguished from levels equal or higher than +4. In the first case the OR value is between 1 and 2 and so the risk is medium, in the second case, the OR value is in the range from 2 to
20 4 and so the risk is high.

For levels of prolidase activity comprised between +1 and +3, the OR values for LBW are in the range from 1 to 2, so it follows that the risk for LBW is medium. Instead, for the same values of prolidase activity the OR values for PTD are below 1 and so the risk of PTD is low or absent.

25 It is to notice that for levels of prolidase activity equal or higher than +4 the

OR value both for LBW and PTD is higher than 4 so that the risk in both cases is very high.

From what described, according to a first embodiment, the method of the invention for the determination of the risk of complications can be carried out in
5 body fluid samples of women with BV.

Finally, in Table 1, data obtained from the analysis of vaginal fluid samples of women colonized by *G. vaginalis* and positive for sialidase or prolidase activity are shown.

In particular, for levels of sialidase activity comprised between +1 and +2, the
10 OR values for LBW and for PTD are in the range from 1 to 2, so it follows that the risk is medium. For levels of sialidase activity equal or higher than +3 the OR value for LBW is in the range from 2 to 4, whereas the OR value for PTD is in the range from 1 to 2. It follows that the risk for LBW is high, whereas the risk for PTD is medium. For levels of sialidase activity equal or higher than +4 the OR values for
15 LBW and for PTD are in the range from 2 to 4 and so for both the pregnancy adverse outcomes the risk is high.

Instead, for levels of prolidase activity comprised between +1 and +2, the OR values for LBW and PTD are in the range from 1 to 2, so it follows that the risk for LBW and PTD is medium. For levels of prolidase activity equal or higher than +3
20 the OR value for LBW is in the range from 2 to 4, so the corresponding risk is high, whereas the OR value for PTD is in the range from 1 to 2, so that the correlated risk is medium. Finally, for levels of prolidase activity equal or higher than +4 the OR value for LBW and for PTD is higher than 4 and so the correlated risk is very high.

From what above described, accordingly with a second embodiment, the
25 method of the invention for the determination of the risk of complications can be

carried out in body fluid samples of women colonized by *G. vaginalis*.

The advantage of these two embodiments of the current invention resides on the opportunity to select women at very high risk that from a simple determination of sialidase and prolidase activity result to have high risk, by a combined
5 bacteriological analysis, or diagnosis of BV, or measurement of the vaginal pH.

As mentioned in the introductive part of the current description, the method of this invention also allows, profitably, to determine the risk of pathologies as acquisition of the HIV viral infection, HPV viral infection, upper genital tract infections (PID), post-partum or post-gynecologic surgery infections, spontaneous
10 abortion, endometritis, cervitis.

In the following part an example regarding a study of acquisition of the HIV viral infection will be described.

For setting the method a group of 50 women at high risk of sexual acquisition of HIV infection was initially enrolled. Three years later, among these women a
15 subgroup of 42 women were still HIV seronegative (controls) and a subgroup of 8 women became HIV seropositive.

These groups were subdivided according to the presence in the body fluid samples of the sialidase activity value, the prolidase activity value, a pH equal or higher than 4.7, diagnosis of bacterial vaginosis (BV), and presence of *G. vaginalis*.

20 Table 2 shows the values of the vaginal enzymatic activities found in the subgroup of the 42 HIV seronegative women (controls) and of the subgroup of the 8 women that became HIV seropositive.

25 TABLE 2

Positive % OR

	Measured parameter and/or vaginal colonization	Seronegative n=42	Seropositive n=8	
	Sialidase activity			
5	≥ +1	64.3	75.0	1.3
	≥ +2	40.5	62,5	1.6
	≥ +3	14.3	50.0	3.6
	≥ +4	9.5	37.5	4.2
	Prolidase activity			
10	≥ +1	83.3	100.0	1.1
	≥ +2	73.8	87.5	1.3
	≥ +3	16.7	50.0	3.2
	≥ +4	11.9	50.0	4.4
15	pH ≥ 4.7	81.0	87.5	1.2
	pH ≥ 4.7 and Sialidase activity			
20	≥ +1	59.5	75.0	1.4
	≥ +2	35.7	62,5	1.8
	≥ +3	14.3	50.0	3.6
	≥ +4	9.5	37.5	4.2
	pH ≥ 4.7 and Prolidase activity			
25	≥ +1	73.8	87.5	1.3
	≥ +2	71.4	87.5	1.4
	≥ +3	14.3	50.0	3.6
	≥ +4	11.9	50.0	4.4
30	BV	71.4	87.5	1.4
	BV and Sialidase activity			
35	≥ +1	54.8	75.0	1.5
	≥ +2	33.3	62.5	2.0
	≥ +3	11.9	50.0	4.3
	≥ +4	9.5	37.5	4.2
	BV and Prolidase activity			
40	≥ +1	73.8	87.5	1.3
	≥ +2	69.0	87.5	1.5
	≥ +3	11.9	50.0	4.3
	≥ +4	9.5	50.0	5.5
45	G. vaginalis	100.0	100.0	1.0

TABLE 2 (continuation)

<i>G. vaginalis</i> and Sialidase activity				
5	≥ +1	64.3	75.0	1.3
	≥ +2	40.5	62.5	1.6
	≥ +3	14.3	50.0	3.6
	≥ +4	9.5	37.5	4.2
<i>G. vaginalis</i> and Prolidase activity				
10	≥ +1	83.3	100.0	1.1
	≥ +2	73.8	87.5	1.3
	≥ +3	16.7	50.0	3.2
	≥ +4	11.9	50.0	4.4

15

The main result shown in Table 2 is the OR value because it represents the index of the risk of acquisition of HIV infection by sexual transmission.

If this ratio is below 1 it means that the woman has a low or no risk of sexual acquisition of the viral infection. A ratio in the range from 1 to 2 is indicative of a medium risk of viral infection acquisition. If the ratio is comprised from 2 to 4 the women is at high risk of viral infection acquisition. Finally, if the ratio is over 4 it means that the woman is at very high risk of viral infection acquisition. In particular, and for example, a medium risk corresponding to an OR value of 2 means that the patient has twice the likelihood of viral infection acquisition in respect to normal women, or, in other words, a risk 100% higher.

25

Preferably, this result can be point out with a score: – meaning a low or no risk, + medium risk, ++ high risk, and +++ very high risk.

Values shown in Table 2 have the same meaning of values in Table 1 showing the data for LBW or PTD, so a detailed comment on will not made.

30

From Tables 1 and 2 it comes out that the OR value has an essentially increasing profile in relation to the increase of the levels of sialidase or prolidase activity.

From here on, an example of determination of the sialidase and prolidase activity in a sample of vaginal fluid will be reported at indicative and not limitative title of the current invention.

5 DETERMINATION OF SIALIDASE ACTIVITY

50 μ l of vaginal fluid sample are incubated for 90 min at room temperature with 50 μ l of 2-(3'-methoxyphenyl)-N-acetyl-D-neuraminic acid (Sigma) substrate dissolved in sodium acetate 50 mM at pH = 5. Samples with sialidase activity develop a red color measurable at 492 nanometers, after addition of a developing solution of 4 mM 4-aminoantipyrine and 6 mM potassium ferricyanide. Results are expressed as difference between the absorbance of the sample after addition of the developing solution and that of a duplicate sample to which the developing reagents are not added. Specific activity was expressed by comparison with a standard curve carried out with known amounts of pure methoxyphenol.

Alternatively, the sialidase activity assay can be performed with chromogenic or fluorogenic substrates different from 2-(3'-methoxyphenyl)-N-acetyl-D-neuraminic acid (Sigma, M1393), as 2-O-(o-nitrophenyl)-alfa-D-N-acetyl neuraminic acid (Sigma, N1266, N1516), 2'-(4-methylumbelliferyl)-alfa-D-N-acetyl neuraminic acid sodium salt (Sigma, M8639), 5-bromo-4-chloro-3-indolyl-alfa-D-N-acetyl neuraminic acid (X-NeuNAc), (Sigma, B 4666; or Calbiochem 203770).

DETERMINATION OF PROLIDASE ACTIVITY

50 μ l of vaginal fluid sample are incubated for 24 hours at 37°C with 50 μ l of L-proline-para-nitroanilide substrate (Sigma) dissolved in 100 mM sodium acetate at pH = 5. Samples with prolidase activity develop a yellow color measured at 405

nanometers. A duplicate sample without the substrate is used to subtract the sample background, whereas the spontaneous hydrolysis of the substrate is subtracted by the average value of two blanks without the vaginal fluid. Results are expressed as milli optical density units (mOD).

5 Alternatively, the assay of prolidase activity can be performed with chromogenic or fluorogenic substrates different from L-proline-para-nitroanilide (Sigma P5267) as: L-proline-beta-naphthylamide (Sigma P1380), N-benzyloxycarbonyl-L-prolyl-beta-naphthylamide, N-benzyloxycarbonyl-L-proline-para-nitrophenyl ester (Sigma C4877), hydroxy-L-prolyl-beta-naphthylamide, L-
10 proline-7-amido-4-methyl-coumarin (Sigma P5898), L-proline-4-methoxy-beta-naphthylamide (Sigma P9655).

A further object of the current invention is a kit for the determination of the risk of pathologies related to the presence of sialidase and/or prolidase activity in samples of body fluid of women.

15 Said kit can comprise a sialidase and/or prolidase activity assay in solution that includes a colorless substrate solution in which to inoculate the biologic sample; a developing solution in a container equipped with dispenser; a reference scale to evaluate the level of the enzymatic activity by the intensity of the developed color.

20 According to an embodiment, said kit can also comprise a sialidase and/or prolidase activity test on solid support, as a platform, comprised of two membranes supported on a solid frame, and containing an enzyme substrate and an agent for the development of the color, through which the biological sample is passed; and a reference scale to evaluate the entity of the enzymatic activity by the intensity of the developed color.

25 According to a further embodiment, said kit can also comprise a sialidase

and/or prolidase activity test on a solid support, comprising a membrane impregnated with a chromogenic or fluorogenic substrate of the enzyme and eventually an agent for the color development, supported on an inert strip, to be touched with the biological sample. Said kit will be furnished with a reference scale to evaluate the
5 entity of the enzymatic activity by the intensity of the developed color.

According to a further embodiment of this invention, said kit can also comprise a pH indicator that is preferably a pH revealing paper with a turning interval in the range between 4 and 7.

It is to be noted that the kit in accord with the invention can profitably be a
10 combined kit. Said kit, for example, can comprise a test in solution or a test on solid support for the determination of the sialidase activity and/or the prolidase activity and a pH indicator.

It is now evident that, with reference to the evaluations contained in the above shown Tables and to the evaluations obtained from the described or anyhow
15 available analytical tests, a kit that can provide in a fast way the determination of the risk of the above described pathologies is of major value to furnish the physician effective tools to decide about the pharmacological cure to administer to patients and to verify the efficacy of therapy.

As can be appreciated from what described, the method to determine the risk
20 of pathologies as low birth weight (LBW), preterm birth (PTD), premature rupture of membranes, intraamniotic infections, spontaneous abortion, endometritis, post-partum and post-gynecologic surgery infections, upper genital tract infections (PID) which cause infertility, cervicitis, susceptibility to sexually transmitted diseases as viral infections from papillomavirus (HPV) and human immunodeficiency virus
25 (HIV), and vertical transmission of HIV infection, accordingly to this invention,

allows to fulfill the demands described in the introductive part of the current invention.

Obviously an expert operator in the field, to satisfy contingent and specific demands, could introduce several modifications and embodiments to the above
5 described method, but all these are contained in the invention as defined by the following claims.

CLAIMS

1. Method for the determination of the risk of pathologies related to the presence of sialidase and/or prolidase activity in body fluid samples of women, comprising the following steps in order:
 - 5 a) determination of the levels of sialidase and/or prolidase activity in said sample of body fluid;
 - b) comparison of said levels of sialidase and/or prolidase activity with ranges of prefixed values of said activity;
 - c) calculation of the risk factor.
- 10 2. Method as set forth in claim 1, in which after the a) step a score of said levels of sialidase and/or prolidase activity is determined.
3. Method as set forth in claim 1 or 2, in which the risk of pathologies is performed in samples of vaginal fluid with pH equal or higher than 4.7.
4. Method as set forth in claim 1 or 2, in which the risk of pathologies is performed
15 in samples of body fluid of women with BV.
5. Method as set forth in claim 1 or 2, in which the risk of pathologies is performed in samples of body fluid of women colonized by the *Gardnerella vaginalis* bacterium.
6. Method as set forth in any one of claims from 1 to 5, in which said method is
20 carried out in samples of vaginal fluid.
7. Method as set forth in any one of claims from 1 to 6, in which the pathologies related to the presence of sialidase and/or prolidase activity include: low birth weight (LBW), preterm birth (PTD), premature rupture of membranes, intraamniotic infections, spontaneous abortion, endometritis, post-partum and post-gynecologic
25 surgery infections, upper genital tract infections (PID) which cause infertility,

cervicitis, susceptibility to sexually transmitted diseases as viral infections from papillomavirus (HPV) and human immunodeficiency virus (HIV), and vertical transmission of HIV infection

8. Method as set forth in any one of claims from 1 to 7, in which said method is
5 carried out in samples of body fluid of women between the first or second trimester of gestation.
9. Method as set forth in any one of claims from 1 to 8, in which said method is carried out in samples of body fluid of women from the seventh to the twenty-fourth full week of gestation.
- 10 10. Method as set forth in any one of claims from 1 to 9, in which said method is carried out in samples of body fluid of pregnant women.
11. Kit for the quantitative determination of the sialidase activity in a sample of body fluid of women.
12. Kit for the quantitative determination of the prolidase activity in a sample of
15 body fluid of women.
13. Kit for the quantitative determination of the sialidase and prolidase activity in a sample of body fluid of women.
14. Kit as claimed in any one of claims from 11 to 13, comprising an illustrative leaflet with a reference scale for the sialidase and/or prolidase activity.
- 20 15. Kit as claimed in any one of claims from 11 to 14, comprising an illustrative leaflet giving the instructions to evaluate the risk of pathologies as: absent or low (-), medium (+), high (++), very high (+++).
16. Kit as claimed in any one of claims from 11 to 15, comprising a test in solution for the determination of the sialidase activity.
- 25 17. Kit as claimed in any one of claims from 11 to 15, comprising a test in solution

for the determination of the prolidase activity.

18. Kit as claimed in any one of claims from 11 to 15, comprising a test in solution for the determination of the sialidase activity and of the prolidase activity.

19. Kit as claimed in any one of claims from 11 to 15, comprising a test on solid support, preferably on reactive strip or platform test, for the determination of the sialidase activity.

20. Kit as claimed in any one of claims from 11 to 15, comprising a test on solid support, preferably on reactive strip or platform test, for the determination of the prolidase activity.

21. Kit as claimed in any one of claims from 11 to 15, comprising a test on solid support, preferably on reactive strip or platform test, for the determination of the sialidase and prolidase activity, respectively.

22. Kit as claimed in claim 11 or 13, comprising as chromogenic or fluorogenic substrate for the determination of sialidase activity a reagent chosen in the group comprising: 2-(3'-methoxyphenyl)-N-acetyl-D-neuraminic acid, 2-O-(o-nitrophenyl)-alfa-D-N-acetyl neuraminic acid, 2'-(4-methylumbelliferyl)-alfa-D-N-acetyl neuraminic acid sodium salt, 5-bromo-4-chloro-3-indolyl-alfa-D-N-acetyl neuraminic acid.

23. Kit as claimed in claim 12 or 13, comprising as chromogenic or fluorogenic substrate for the determination of prolidase activity a reagent chosen in the group comprising: L-proline-para-nitroanilide, L-proline-beta-naphthylamide, N-benzyloxycarbonyl-L-prolyl-beta-naphthylamide, N-benzyloxycarbonyl-L-proline-para-nitrophenyl ester, hydroxy-L-prolyl-beta-naphthylamide, L-proline-7-amido-4-methyl-coumarin, L-proline-4-methoxy-beta-naphthylamide.

24. Kit as claimed in any one of claims from 11 to 23, comprising a pH indicator.

25. Kit as claimed in claim 24 comprising the reference scales for pH, and/or sialidase activity, and/or prolidase activity.

26. Kit as claimed in claim 24 comprising a leaflet giving the instructions to evaluate the risk of pathologies as: absent or low (-), medium (+), high (++), very high (+++).

5

INTERNATIONAL SEARCH REPORT

International Application No

PC1/T 01/00069

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/50 C12Q1/34 C12Q1/37

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MCGREGOR J A ET AL: "BACTERIAL VAGINOSIS IS ASSOCIATED WITH PREMATURITY AND VAGINAL FLUID MUCINASE AND SIALIDASE: RESULTS OF A CONTROLLED TRIAL OF TOPICAL CLINDAMYCIN CREAM"</p> <p>AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 170, no. 4, April 1994 (1994-04), pages 1048-1060, XP002901155</p> <p>ISSN: 0002-9378</p> <p>abstract</p> <p>table IV</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1,2,</p> <p>4-11,</p> <p>14-22,</p> <p>24-26</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

7 January 2002

Date of mailing of the international search report

15/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoekstra, S

INTERNATIONAL SEARCH REPORT

International Application No

PC1/1T 01/00069

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BRISLIDEN A M ET AL: "SIALIDASES (NEURAMINIDASES) IN BACTERIAL VAGINOSIS AND BACTERIAL VAGINOSIS-ASSOCIATED MICROFLORA"</p> <p>JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 30, no. 3, March 1992 (1992-03), pages 663-666, XP002901154</p> <p>ISSN: 0095-1137</p> <p>the whole document</p> <p>---</p>	<p>1,2, 4-11, 14-22, 24-26</p>
X	<p>WO 00 55354 A (CORFIELD TONY ; MILLAR MICHAEL (GB); SOOTHILL PETER (GB); UNIV BRIS) 21 September 2000 (2000-09-21)</p> <p>the whole document</p> <p>---</p>	<p>1,2, 4-11, 14-22, 24-26</p>
X	<p>US 5 571 684 A (LAWRENCE PAUL J ET AL) 5 November 1996 (1996-11-05)</p> <p>the whole document</p> <p>column 2, line 51 -column 3, line 56</p> <p>---</p>	<p>1,2,4-6, 8-10,12, 14-21, 23-26</p>
X	<p>WO 00 24753 A (IBBEX INC) 4 May 2000 (2000-05-04)</p> <p>the whole document</p> <p>-----</p>	<p>11,16-22</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IT 01/00069

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0055354	A	21-09-2000	AU 3306600 A EP 1163361 A2 WO 0055354 A2	04-10-2000 19-12-2001 21-09-2000
US 5571684	A	05-11-1996	AT 184654 T AU 4135096 A CA 2202993 A1 DE 69512263 D1 DE 69512263 T2 EP 0791071 A1 WO 9615255 A2 TW 408182 B	15-10-1999 06-06-1996 23-05-1996 21-10-1999 31-05-2000 27-08-1997 23-05-1996 11-10-2000
WO 0024753	A	04-05-2000	AU 1202899 A EP 1124836 A1 WO 0024753 A1	15-05-2000 22-08-2001 04-05-2000